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In this study, we attempt to target both the urokinase plasminogen activator and the mitogen-activated protein kinase
pathway in acutemyeloid leukemia (AML) cell lines andprimaryAMLblasts usingPrAgU2/LF, a urokinase-activated anthrax
lethal toxin. PrAgU2/LF was cytotoxic to five out of nine AML cell lines. Cytotoxicity of PrAgU2/LF appeared to be
nonapoptotic andwasassociatedwithMAPKactivation andurokinaseactivity becauseall thePrAgU2/LF-sensitive cell lines
showed both uPAR expression and high levels of MEK1/2 phosphorylation. Inhibition of uPAR or desensitization of cells to
MEK1/2 inhibition blocked toxicity of PrAgU2/LF, indicating requirement for both uPAR expression andMAPK activation for
activity. PrAgU2/LF was also cytotoxic to primary blasts from AML patients, with blasts from four out of five patients
showing a cytotoxic response to PrAgU2/LF. Cytotoxicity of primary AML blasts was also dependent on uPAR expression
and phos-MEK1/2 levels. CD34
+ bone marrow blasts and peripheral blood mononuclear cells lacked uPAR expression and
were resistant to PrAgU2/LF, demonstrating the lack of toxicity to normal hematological cells and, therefore, the tumor
selectivity of this approach. Dose escalation in mice revealed that the maximal tolerated dose of PrAgU2/LF is at least 5.7-
fold higher than that of the wild-type anthrax lethal toxin, PrAg/LF, further demonstrating the increased safety of this
molecule.Wehaveshown, in this study, thatPrAgU2/LF is anovel, dual-specificmolecule for theselective targetingofAML.
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Although a high proportion of acute myeloid leukemia (AML)
patients enter complete remission following combination induction
and consolidation chemotherapy, most relapse because of persistence
of chemotherapy-resistant blasts [1,2]. Hence, alternative approaches
using more selective mechanisms for targeting AML are needed.
Anthrax lethal toxin (PrAg/LF) is a binary toxin consisting of two
proteins: protective antigen (PrAg) and lethal factor (LF) [3,4]. PrAg
binds cells through its ubiquitously expressed receptors tumor endothelial
marker–8 and capillarymorphogenesis gene–2 and is cleaved by furin-like
proteases leading to the generation of an active 63-kDa fragment (PrAg63)
[5]. PrAg63 then forms oligomers, binds three to four molecules of LF,
and undergoes endocytosis [6]. Upon acidification of the endosome,
PrAg63 oligomers undergo a conformational change leading to pore
formation and translocation of LF into the cytosol [7]. LF is a zinc
metalloprotease that cleaves mitogen-activated protein/extracellular
regulated kinase kinases (MEKs), leading to the inhibition of the
MAPK pathway [8,9]. We and others have previously demonstrated the
potential for selectively targeting of a number of different tumor types,
including melanoma and AML, using anthrax lethal toxin [10,11].
However, tumor selectivity of PrAg/LF remains relatively limited due to
its in vivo toxicity and the inability of some normal cells to survive the
inhibition of the MAPK pathway [11,12].
To enhance the selectivity of PrAg/LF, we sought to exploit
additional tumor-specific markers absent from normal cells. One such
marker is the urokinase plasminogen activator. This cell surface serine
protease consists of the urokinase plasminogen activator (uPA) and its
glycosyl-phosphatidyl inositol–anchored receptor (uPAR) [13,14].
uPA is released as pro-uPA, the single-chain inactive form, which is
cleaved into active uPA by plasmin. Active uPA binds to uPAR,
forming a potent protease system that cleaves plasminogen into
plasmin. In the absence of uPAR, uPA is rapidly inhibited by the
plasminogen activator inhibitor 1, hence the importance of uPAR
expression for the stabilization of uPA and the activity of the
urokinase plasminogen activator system. AML blasts overexpress uPA
and uPAR, whereas most normal tissues do not, hence the potential
for targeting this system in AML [15–17].
We therefore replaced the furin cleavage sequence of PrAg
164RKKR167 with a urokinase-specific cleavage sequence
163PGSGRSA169 termed U2 [18,19]. The resulting urokinase-activated
recombinant anthrax lethal toxin, PrAgU2/LF, is a dual-selective toxin
that targets two distinct tumor-specific markers: expression of the uPA/
uPAR system and dependence on the MAPK pathway for survival.
We have previously targeted theMAPK pathway in AML using PrAg/
LF [20]. We have also demonstrated the potential for targeting two
separate tumor markers in AML using DTU2GMCSF, a urokinase-acti-
vated fusion of diphtheria toxin and the granulocyte macrophage colony
stimulating factor [21]. Here we describe the specificity, range, potency,
and targeting mechanisms of PrAgU2/LF, a dual-selective toxin that
simultaneously targets a cell surface system (uPA/uPAR) and an essential
signaling pathway, the Ras-Raf-MEK1/2-ERK1/2 pathway.
Materials and Methods
Expression and Purification of PrAgU2/LF
Recombinant PrAgU2, PrAg, and LF (wild-type) were expressed
and purified as described previously [18,22].
Cells and Cell Lines. Human AML cell lines HL60, U937, ML1,
ML2, Mono-Mac-1, Mono-Mac-6, TF1-vRaf, TF1-vSrc, andTF1-HaRas and human CD34
+ progenitor bone marrow blasts were
grown as described previously [20,23].
Human peripheral blood mononuclear cells were isolated from
samples collected from healthy adults (n = 5) following informed
consent, as described previously [23].
Primary blasts were isolated fromblood or bonemarrow collected from
five AML patients following informed consent, as described previously
[23].One patient (case 5) was positive for FLT3-ITDmutations, whereas
the remaining four patients (cases 1 through 4) were not. Studies with
human patient materials were performed in accord with the institutional
review board–approved protocol LAU.SOAS.RA1.28/Jun/12.
Proliferation Inhibition Assay (Cytotoxicity). The proliferation
inhibition assay was carried out as described previously [20,23]. Briefly,
cells containing 10−9 M LF were plated in a flat-bottom 96-well plate
(Corning Inc., Corning, NY). PrAgU2 or PrAg was added at
concentrations ranging from 10−8 to 10−13M, and plates were incubated
for 48 hours. U0126 was added as described above but in concentrations
ranging from 10−4 to 10−9 M. XTT cell proliferation reagent (Roche,
Basel, Switzerland) was added, and absorbance was read at 450 nm.
Absorbance was plotted against log of concentration and a nonlinear
regression with a variable-slope sigmoidal dose–response curve, and an
IC50 value was generated using GraphPad Prism 5 software (GraphPad
Software, San Diego, CA). An IC50 value was generated only if cell
survival decreased below 50% for at least the two highest concentration
points used. If not, cells were considered nonsensitive, and the IC50 value
was considered to be higher than 10,000 pM, the highest concentration of
PrAg used in this assay.
Cell Cycle Analysis
Cell cycle effect analysis was carried out using propidium iodide
(PI) staining on flow cytometry as described previously [20]. Briefly,
cells incubated with PrAgU2/LF (10−8 M PrAg/10−9 M LF) or
media alone for 24 and 48 hours at 37°C/5% CO2 were harvested
and fixed in 70% ethanol for a minimum of 24 hours at −20°C. Cells
were then incubated with a PI staining solution (50 μg/ml) for 40
minutes at 37°C. Samples were then read on a C6 flow cytometer
(BD Accuri, Ann Arbor, MI), and total cell DNA content was
measured on FL2-A with cells gated on width versus forward scatter.
Analysis of Cell Cytotoxicity
Type of cell death was determined using an annexin V–fluorescin
Isothiocyanate (annexin V–FITC) and PI apoptosis detection kit
(Abcam, Cambridge, MA) and an FITC-conjugated active caspase
inhibitor (ApoStat Apoptosis Detection Kit, R&D Systems, Abingdon,
England) on flow cytometry, as described previously [20]. Briefly, cells
were incubated with either medium alone (control cells) or medium
containing PrAgU2/LF at the highest concentration used in the
cytotoxicity assay (10−8 M PrAg/10−9 M LF) for 24 and 48 hours at
37°C/5% CO2. Cells were then harvested and incubated with an
FITC-conjugated annexin V antibody (2.5 mg/ml) and PI (5 mg/ml) for
45minutes at 37°Cor incubatedwith 0.5μg/ml of apostat for 30minutes
then harvested. Cells were then read using a C6 flow cytometer (i, Ann
Arbor, MI). Annexin V/PI data were analyzed on FL1-H versus FL2-H
scatter plot, and active caspases were detected on FL1-H. Cells were gated
on width versus forward scatter.
uPAR Expression
Expression of uPAR was determined using single cell staining on
flow cytometry as described previously [20]. Cells were incubated
Table 1. uPAR Expression, Phospho-MEK1/2 Levels, and Potency of PrAgU2/LF and PrAg/LF on
AML Cell Lines
Cell Line PrAgU2/LF
(IC50, pmol/L)
PrAg/LF
(IC50, pmol/L)
Phospho-MEK1/2
(RFI)
uPAR (RFI)
HL-60 56 18 2.11 (++) 3.25 (++)
TF1-vSrc 12 14 2.62 (++) 2.77 (++)
TF1-VRaf 46 23 12.68 (++) 2.76 (++)
Mono-Mac-6 53 42 2.54 (++) 1.82 (+)
ML-2 151 77 2.85 (++) 3.10 (++)
TF1-HaRas N10,000 N10,000 1.38 (−) 2.31 (++)
ML-1 N10,000 N10,000 0.91 (−) 2.82 (++)
U937 N10,000 N10,000 2.58 (++) 6.11 (++)
Mono-Mac-1 N10,000 N10,000 2.52 (++) 3.01 (++)
(++) strongly positive (RFI N 2.0), (+) weakly positive (1.5 b RFI b 2.0), (−) negative (RFI b 1.5).
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Signaling Technology, Danvers, MA). An FITC-conjugated mouse IgG
was used as isotypic control. Positivity was determined using the ratio of
fluorescence intensity (RFI) between the mean fluorescence intensity
(MFI) of uPAR stained cells and that of isotypic control. An RFI value ≥
2.0 was considered strongly positive, whereas an RFI between 1.5 and 2.0
was considered weakly positive for uPAR expression. An RFI value b 1.5
was considered negative for uPAR expression.
Intracellular Staining and Flow Cytometry Analysis
Activation of the MEK1/2-ERK1/2 pathway in AML cell lines
[untreated and following incubation with PrAgU2/LF (10−8 MPrAgU2/
10−9 MLF)] was assessed by determining the levels of phospho-MEK1/2
using flow cytometry as described previously [20]. Cells were fixed in
70% ethanol for 15minutes then incubated with anti-phospho-MEK1/2
rabbitmonoclonal antibodies (Cell Signaling Technology) followed by an
FITC-conjugated mouse anti-rabbit polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). Cells stained only with FITC-conju-
gatedmouse anti-rabbit polyclonal antibodywere used as isotypic control.
Samples were analyzed using a C6 flow cytometer (BD Accuri) and gated
on width versus forward scatter. Positivity was determined using the RFI
between the mean fluorescence intensity of the stained cells and that of
the isotypic control. RFI ≥ 2.0 was considered strongly positive, whereas
an RFI between 1.5 and 2.0 was considered weakly positive for
phospho-MEK1/2. An RFI value b 1.5 was considered negative for
phospho-MEK1/2.
Blocking Assays
Cells were grown in the presence of 1 μM U0126 (Cell Signaling
Technology) for 8 to 10 passages and then treated with PrAg/LF and
PrAgU2/LF for 48 hours, or 10 μg/ml of monoclonal anti-uPA
antibody (American Diagnostica, Lexington, MA) was added to cells
upon plating, followed by a cytotoxicity assay as described above.
In Vivo Toxicity Studies
Balb/c mice (5 to 10 mice per group) were injected intraperitoneally
with 200 μl of either vehicle alone (phosphate-buffered saline) or
increasing doses of PrAg/LF or PrAgU2/LF (5:1 ratio of PrAg or PrAgU2
to LF, given simultaneously) every other day for a total of three injections,
as described previously [24]. PrAg/LF was administered at cumulative
doses of 9, 12, 15, 18 and 21 μg of total LF, whereas PrAgU2/LF was
administered at cumulative doses of 21, 30, 36, 45 and 51 μg of total LF.
All mice were euthanized at day 15 postinjection. Samples from heart,
lungs, liver, spleen, duodenum, colon, and kidneyswere removed, fixed in
10% formaldehyde, and embedded in paraffin. Histologic analysis of
hematoxylin and eosin (H&E)–stained sections was performed, and
tissue damage was graded as minimal, mild, moderate, or severe.
Statistical Analysis
Wilcoxon two-sample test was used to compare sensitive versus
nonsensitive cells. Statistical analyses were done using GraphPad
Prism5 software. All experiments were carried out three times.
Results
Cytotoxicity of PrAgU2/LF to AML cell lines
PrAgU2/LF was cytotoxic to five out of the nine AML cell lines
tested (56%), with IC50 values ranging from 12 to 151 pM, whereas
the remaining four cell lines were not sensitive to its cytotoxic effects
(IC50 N 10,000 pM). This indicates that the majority of AML celllines are highly sensitive to the dual targeting of the urokinase
plasminogen activator and the MAPK pathway (Table 1, Figure 1).
To determine the response of AML cell lines to the inhibition of the
MAPK pathway independently of urokinase activity, we tested their
sensitivity to the furin-activated version of the molecule, PrAg/LF.
The furin-activated PrAg/LF showed the same pattern of cytotoxicity
observed with the urokinase-activated PrAgU2/LF, with the four cell
lines that were resistant to PrAgU2/LF being also resistant to PrAg/LF
(Table 1). This indicates that the lack of cytotoxic response in these
cell lines is due to their lack of sensitivity to the LF-mediated
inhibition of the MAPK pathway. The same four cell lines were also
resistant to the small–molecular weight MEK1/2 inhibitor U0126
(data not shown), further confirming their resistance to the inhibition
of the MAPK pathway.
Cell Cycle Effect of PrAgU2/LF
To determine whether, in addition to cytotoxicity, PrAgU2/LF
induces cell cycle arrest in AML cells, we examined the cell cycle
status in the surviving fraction of cells following treatment with
PrAgU2/LF. Cell cycle arrest was observed in a total of four AML cell
lines at both 24- and 48-hour incubation, with the remaining five cell
lines not showing cell cycle arrest following treatment. All four cell
lines showed an increase in the percentage of cells in the G0/G1 phase
in the surviving cell fraction at both 24 (data not shown) and 48 hours
(Figure 2A). The percentage of cells in G0/G1 increased from 51.3 ±
3.06 to 76.9 ± 2.5 (P = .0026), from 45.3 ± 3.6 to 74.3 ± 3.1 (P =
.0006), from 41.6 ± 1.6 to 57.6 ± 4.2 (P = .0009), and from
40.5 ± 1.8 to 65.7 ± 2.7 (P = .0009) in HL60, ML-2, TF1-HaRas,
and ML-1 cells, respectively, following treatment with PrAgU2/LF
for 48 hours (Figure 2B), indicating that, in addition to cytotoxicity,
PrAgU2/LF induces cell cycle arrest in AML cell lines. Interestingly,
the observed pattern of cell cycle arrest did not correspond to that of
cytotoxicity, with two of the arrested cell lines belonging to the group
that showed a cytotoxic response (HL60 and ML-2) and the other
two belonging to the group that was resistant to the cytotoxic effects
of PrAgU2/LF (ML-1 and TF1-HaRas). This indicates that the
cytotoxic and cytostatic effects of PrAgU2/LF may be mediated
through different mechanisms.
Analysis of Cell Cytotoxicity
The mechanism of cell death observed following treatment with
PrAgU2/LF was determined using annexin V staining and caspase
activation. Treatment with PrAgU2/LF caused an increase in both
annexin V and PI staining in all cell lines at both 24- and 48-hour
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Figure 1. Nonlinear regression curves of the cytotoxicity of both PrAgU2/LF and PrAg/LF on AML cell lines HL60 (A), TF1-vSrc (B), and
TF1-vRaf (C) along with a compilation of representative nonlinear regression curves of the cytotoxicity of PrAgU2/LF to all nine AML cell
lines tested. Cell lines in red are sensitive to PrAgU2/LF.
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increase in PI staining indicates loss of membrane integrity following
treatment which may be indicative of nonapoptotic cell death.
Furthermore, treatment with PrAgU2/LF did not induce caspase
activation in any of the treated cell lines, as evidenced by the negative
staining obtained with a cell-permeable, FITC-conjugated, active caspase
inhibitor (Figure 2, C and D). The lack of apparent caspase activation,
associated with the loss of membrane integrity, indicates that PrAgU2/LF
induces caspase-independent, nonapoptotic death in AML cells.
Expression of uPAR
To investigate the underlying mechanisms of the activity of
PrAgU2/LF, we first examined the expression of the uPA/uPAR
protease system on AML cell lines by determining uPAR expression
levels. All AML cell lines tested expressed uPAR, with eight showing
high uPAR expression levels (RFI N 2.0) and only one cell line being
weakly positive for uPAR expression (Mono-Mac-6, RFI = 1.82)
(Table 1, Figure 3A), indicating that AML cell lines express uPAR
and are capable of activating PrAgU2/LF. The fact that the four cell
lines that were resistant to PrAgU2/LF (TF1-HaRas, ML-1,
Mono-Mac-1, and U937) express uPAR further indicates that their
resistance to the cytotoxicity of PrAgU2/LF is due to their lack of
dependence on the MAPK pathway for survival and not to their
inability to activate the toxin.
Analysis of MAPK Activation
To demonstrate that the cytotoxicity of PrAgU2/LF is dependent
on the MAPK pathway, we investigated the activation level of theMEK1/2-ERK1/2 branch of the pathway by determining basal levels
of phospho-MEK1/2 in AML cells. All five PrAgU2/LF-sensitive cell
lines (HL60, ML-2, Mono-Mac-6, TF1-vRaf, and TF1-vSrc) were
strongly positive for phospho-MEK1/2 with RFI values ranging from
2.11 to 12.68, demonstrating that the MAPK pathway is active in
these cells (Table 1, Figure 3B). This indicates that sensitivity of AML
cell lines to PrAgU2/LF is dependent on phospho-MEK1/2 levels
because all sensitive cell lines had high levels of phospho-MEK1/2.
Moreover, treatment with PrAgU2/LF completely inhibited MEK1/2
phosphorylation in these cell lines, further demonstrating that
cytotoxicity of PrAgU2/LF is mediated through the inhibition of
the MAPK pathway (Supplemental data). On the other hand, out of
the four PrAgU2/LF-resistant cell lines, two were negative for
phospho-MEK1/2 (TF1-HaRas and ML-1; RFI = 1.38 and 0.91,
respectively), whereas the remaining two cell lines were positive for
phospho-MEK1/2 (Mono-Mac-1 and U937; RFI = 2.58 and 2.52,
respectively) (Table 1, Figure 3B). Treatment with PrAgU2/LF
completely inhibited phosphorylation of MEK1/2 in the two cell lines
that had high basal levels of phospho-MEK1/2 (Mono-Mac-1 and
U937), indicating that resistance of these cell lines is not due to the
lack of inhibition of the MEK1/2-ERK1/2 pathway but rather to
their resistance to its inhibition (Supplemental data). Hence, factors
other than activation level may affect the susceptibility of AML cell
lines to the inhibition of the MAPK pathway.
Blocking Assays
To further demonstrate that the activity of PrAgU2/LF requires
both expression of uPA/uPAR and dependence on the MAPK
Figure 2. Representative graphs of cell cycle analysis of HL60, ML2, ML1, and TF1-HaRas cells following treatment with PrAgU2/LF for 48
hours (A). Cells in G0/G1 and G2/M are gated M2 and M3, respectively. Percentage of cells in G0/G1 following treatment with PrAgU2/LF
compared with controls (B). Representative graphs of annexin V/PI and active caspase staining of HL60 (C) and TF1-vRaf (B) cells treated
with PrAgU2/LF (red) for 24 hours. Annexin V–FITC is detected on FL1-H and PI on FL2-H. Treated cells are positive for both annexin V and
PI with no sign of caspase activation.
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impact on the activity of PrAgU2/LF. Addition of a neutralizing
anti-uPA antibody either greatly reduced or completely inhibited the
cytotoxicity of PrAgU2/LF to HL60 and ML-2 cells, with IC50 values
increasing from 13 and 29 pM to 1602 and N 10,000 pM,
respectively, at 48 hours in the presence of the antibody (Figure 4A
and B, ). This demonstrates that the expression of an active uPA/
uPAR system on AML cells is essential for the activity of PrAgU2/LF.
Desensitization of HL60 cells to MEK1/2 inhibition, through growth
in the presence of U0126, led to desensitized cells becoming resistant
to PrAgU2/LF (Figure 4C). Desensitized HL60 cells had a mean
survival of 92% compared with 47% for control cells (P b .0001) after
treatment with PrAgU2/LF for 48 hours (Figure 4C). This indicates
that cell dependence on the MAPK pathway is essential for the
activity of PrAgU2/LF in AML cells.
Cytotoxicity of PrAgU2/LF to Primary AML Blasts
After determining potency of PrAgU2/LF on AML cell lines, we
tested its activity on primary blasts isolated from five AML patients.
PrAgU2/LF was highly cytotoxic to AML blasts from four out of five
patients (cases 2, 3, 4, and 5), with IC50 values ranging from 3.0 to
9.0 pM, whereas blasts from only one patient (case 1) were resistant tothe cytotoxic effects of PrAgU2/LF, with an IC50 N 10,000 pM
(Table 2, Figure 5A). This demonstrates that the majority of primary
AML blasts tested, including one carrying the FLT3-ITD, are
sensitive to the PrAgU2/LF-dependent dual targeting of both the
uPA/uPAR system and the MAPK pathway. Blasts from case 1 were
also resistant to the furin-activated PrAg/LF (IC50 N 10,000 pM),
indicating their resistance to the inhibition of the MAPK pathway.
Analysis of uPAR Expression and MAPK Activation in
Primary AML Blasts
To investigate the mechanisms underlying the activity of PrAgU2/
LF in primary AML blasts, we determined their uPAR expression
pattern and their basal levels of MEK1/2 phosphorylation. Blasts
from all five patients expressed uPAR, with four expressing high levels
of uPAR (cases 1, 2, 3, and 4; RFI values ranging from 2.11 to 35.28)
and only one being weakly positive for uPAR expression (case 5;
RFI = 1.74) (Table 2, Figure 5B). Similarly to AML cell lines,
primary blasts from AML patients do express uPAR and are,
therefore, capable of activating PrAgU2/LF. Of the four primary
AML blasts that showed a cytotoxic response following treatment
with PrAgU2/LF, three were positive for phospho-MEK1/2 (cases 3,
4, and 5), with blasts from only one patient (case 2) showing no
Figure 3. Expression of uPAR on AML cell lines ML2, HL60, U937, and Mono-Mac-6 (A). Cells stained for uPAR are in red; and isotypic
control, in black. All four cell lines are positive for uPAR expression. (B) Phospho-MEK1/2 levels in the PrAgU2/LF-sensitive AML cell lines
ML-2 and HL60 and the PrAgU2/LF-resistant cell lines Mono-Mac-1 and ML-1. Cells stained for phospho-MEK1/2 are in red; and isotypic
control, in black. ML2, HL60, and Mono-Mac-1 are positive for phospho-MEK1/2, whereas ML1 cells are negative.
352 Dual targeting of uPA and MAPK pathway in AML Bekdash et al. Translational Oncology Vol. 8, No. 5, 2015phosphorylated MEK1/2 (Table 2, Figure 5C). This confirms data
obtained in AML cell lines and further indicates that the cytotoxic
response to treatment with PrAgU2/LF in primary blasts is, for the most
part, dependent on high basal levels of phosphorylated MEK1/2.
PrAgU2/LF Toxicity to Normal Cells
To demonstrate that the addition of a second tumor-selectivity
criterion, in the form of urokinase activation, increases the tumor
selectivity of PrAgU2/LF compared with the furin-activated PrAg/LF,
we tested its cytotoxicity to normal peripheral mononuclear cells and
to CD34
+ progenitor bone marrow blasts. Normal peripheral
mononuclear cells were sensitive to the cytotoxicity of the
furin-activated PrAg/LF (IC50 = 15 pM) but resistant to PrAgU2/
LF (IC50 N 10,000 pM), demonstrating that addition of the urokinase
activation step decreases the toxicity of PrAgU2/LF to normal cells,
hence increasing its tumor selectivity (Table 2, Figure 5D). It also
indicates that the lack of cytotoxicity of PrAgU2/LF to normal
peripheral mononuclear cells is due to the absence of an active
urokinase system on the cell surface. Similarly, CD34
+ progenitor bone
marrow blasts were resistant to the cytotoxic effects of PrAgU2/LF,
with an IC50 N 10,000 pM, further confirming the selective
cytotoxicity of PrAgU2/LF to AML blasts and its lack of toxicity tonormal hematological cells (Table 2, Figure 5E). The furin-activated
PrAg/LF was considered noncytotoxic to CD34
+ progenitor bone
marrow blasts because cell survival did not decrease below 50% at the
highest two concentration points as specified in the Materials and
Methods section. However, as illustrated in Figure 5E, a slight
decrease in viability was observed with increasing concentrations of
PrAg/LF, which was not the case when these cells were treated with
PrAgU2/LF, further demonstrating that the addition of the
urokinase-activation requirement decreases the toxicity of PrAgU2/
LF to normal cells and, subsequently, increases its tumor selectivity.
The lack of toxicity of PrAgU2/LF to CD34
+ progenitor bone marrow
blasts was underlined by their inability to activate the toxin as
illustrated by the lack of uPAR expression (RFI = 1.15) on these cells
(Table 2, Figure 5F).
In Vivo Safety
To determine the safety of PrAgU2/LF, we carried out a
dose-escalation study in Balb/c mice. No mortality was observed
for PrAgU2/LF at any of the doses, including the highest total LF
dose of 51 μg (85 μg of PrAgU2/17 μg of LF). The only dose at
which no mortality was observed with PrAg/LF was the lowest total
LF dose of 9 μg (15 μg of PrAg/3 μg of LF). Mortality rates ranging
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Figure 4. Nonlinear regression curves of the cytotoxicity of PrAgU2/LF to HL60 (A) and ML2 (B) cells in the presence of a neutralizing
anti-uPA antibody. Inhibition of uPA/uPAR greatly decreases or completely inhibits the activity of PrAgU2/LF. Impact of the desensitization
of HL60 cells to MAPK inhibition on the activity of PrAgU2/LF (C), with desensitized cells being resistant to PrAgU2/LF at 48 hours
compared with control cells.
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up to the highest total LF dose of 21 μg (35 μg of PrAg/7 μg of LF)
(Figure 6A). Hence, the total dose of LF delivered using PrAgU2
without causing mortality is at least 5.7-fold higher than that
delivered using PrAg, indicating that the introduction of a
urokinase-activation step greatly enhances the safety and tumor
selectivity of this toxin.
Histological analysis revealed the presence of microscopic foci of
perivenular, periportal, and lobular necroinflammation in the livers of
mice in the PrAg/LF treatment groups starting at a total LF dose of 9
μg (15 μg of PrAg/3 μg of LF) (moderate to severe) and also in the
livers of mice in the PrAgU2/LF treatment groups, but to a much
lesser extent (mild to moderate) and only at the three highest total LF
doses tested of 36 μg (60 μg of PrAgU2/12 μg of LF), 45 μg (75 μg of
PrAgU2/15 μg of LF), and 51 μg (85 μg of PrAgU2/17 μg of LF)(Figure 6, B–E), with no damage observed at any other dose level. No
sign of damage in any other organ was detected in any of the
treatment groups.
Discussion
We have recently shown that a majority of AML cell lines are
dependent on the MAPK pathway for survival and are, therefore,
sensitive to the PrAg/LF-dependent inhibition of the MAPK pathway
[20]. Although PrAg/LF is considered tumor selective because most
normal cells and tissues can survive the inhibition of the MAPK
pathway, its safety is limited by its in vivo toxicity [11,12]. To
enhance the tumor selectivity of PrAg/LF, we sought to target an
additional tumor marker: the urokinase plasminogen activator cell
surface protease. We and others have shown the expression of uPA/
uPAR on a large number of tumor types, including AML [17,25,26].
Table 2. uPAR Expression, Phospho-MEK1/2 Levels, and Potency of PrAgU2/LF and PrAg/LF on
Primary AML Blasts and Normal Hematopoietic Cells
Cells PrAgU2/LF
(IC50;pmol/L)
PrAg/LF
(IC50;pmol/L)
uPAR (RFI) Phospho-
MEK1/2 (RFI)
Primary AML blasts
Case 1 N10,000 N10,000 3.11 (++) NA
Case 2 8.0 3.0 7.85 (++) 1.04 (−)
Case 3 6.0 4.0 4.62 (++) 2.72 (++)
Case 4 3.0 2.0 35.28 (++) 1.65 (+)
Case 5 9.0 6.0 1.84 (+) 2.49 (++)
Normal hematopoietic cells
Peripheral blood mononuclear
cells
N1000 15 NA NA
CD34
+ bone marrow progenitor
blasts
N10,000 N10,000 1.15 (−) NA
(++) strongly positive (RFI N 2.0), (+) Weakly positive (1.5 b RFI b 2.0), (−) negative (RFI b 1.5).
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urokinase-activated protective antigen (PrAg) in which the furin
activation site 164RKKR167 is replaced by a uPA/uPAR cleavage site,
163PGSGRSA169, termed U2, limiting the activation of the resulting
protective antigen (PrAgU2) to uPA/uPAR-expressing tumors [18].
To maintain targeting of the MAPK pathway while enhancing tumor
selectivity, we tested the combination of the urokinase-activated
version of protective antigen (PrAgU2) along with the MAPK-inhi-Figure 5.Nonlinear regression curves of the cytotoxicity of PrAgU2/LF
to all but one of the primary blasts tested (case 1). Expression of uPAR
uPAR expression. (C) Phospho-MEK1/2 levels in primary blasts fr
phospho-MEK1/2. Cytotoxicity curves of both PrAgU2/LF and PrAg/LF
blasts (E). PrAgU2/LF is not toxic to either cell type and shows an enha
CD34
+ progenitor bone marrow blasts (F). Progenitor blasts are negativ
antibody are in red; and the isotypic control, in black.biting catalytic moiety LF. Thus, PrAgU2/LF would retain the
potency and range observed with PrAg/LF while enhancing AML
specificity through urokinase activation. Hence, PrAgU2/LF would
constitute a dual-selective toxin that targets two separate AML
markers: expression of urokinase plasminogen activator and depen-
dence on the MAPK pathway.
PrAgU2/LF had a similar potency and range to PrAg/LF, showing
a significant cytotoxic effect on five out of the nine AML cell lines
tested. The four4 cell lines that were resistant to PrAgU2/LF
expressed high levels of uPAR and were also resistant to the
furin-activated PrAg/LF as well as to the small–molecular weight
MEK1/2 inhibitor U0126, indicating resistance to the inhibition of
the MAPK pathway. The five cell lines that were sensitive to this
dual-selective molecule expressed uPAR and had high levels of
phosphorylated MEK1/2, indicating that the presence of an active cell
surface uPA/uPAR system and the dependence on the MAPK
pathway for survival are essential underlying requirements for the
sensitivity of AML cells to the cytotoxic effects of PrAgU2/LF. This
was further illustrated by the loss of sensitivity when either one of
these components was blocked. Inhibition of the uPA/uPAR system
or development of resistance to the inhibition of the MAPK pathway
greatly decreased or completely reversed sensitivity of AML cells to
PrAgU2/LF and demonstrated that PrAgU2/LF is a dual-selective
toxin that requires both an active uPA/uPAR system and dependenceto primary blasts from five AML patients (A). PrAgU2/LF is cytotoxic
on primary blasts from cases 2, 3, and 4 (B), all of which positive for
om cases 2, 3, 4, and 5, with only case 2 being negative for
to peripheral blood mononuclear cells (D) and CD34
+ bone marrow
nced safety profile compared with PrAg/LF. Expression of uPAR on
e for uPAR expression (RFI = 1.15). Cells stained with the specific
Figure 5. (continued).
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tumor markers are not likely to be found simultaneously in normal
cells, ensuring the safety and tumor selectivity of this approach.
However, the fact that two of the AML cell lines that were resistant
to the cytotoxicity of PrAgU2/LF did show high levels of
phospho-MEK1/2 indicates that the activation level of the MAPK
pathway, expressed as phospho-MEK1/2 levels, though a useful
marker cannot be the sole indicator of a cells dependence on the
MAPK pathway for survival.
Importantly, the potency and range observed with PrAgU2/LF in
AML cell lines were confirmed in primary blasts from AML patients,
with PrAgU2/LF being cytotoxic to blasts from four out of five
patients tested, including one with FLT3-ITD. Moreover, cytotox-
icity of PrAgU2/LF to primary AML blasts was dependent on uPAR
expression and phospho-MEK1/2 levels, confirming the requirement
for the simultaneous presence of both markers for the activity of
PrAgU2/LF. Importantly, introduction of the urokinase activation
sequence in PrAgU2/LF greatly enhanced its tumor specificity and,
subsequently, its safety, with both normal human peripheral
mononuclear cells and CD34
+ progenitor bone marrow blasts being
resistant to PrAgU2/LF, indicating the tumor selectivity of this
dual-specific targeted toxin. This was confirmed in an in vivo mouse
safety model which showed that the total dose of LF that could be
delivered to mice without causing mortality was at least 5.7-fold
higher when delivered using PrAgU2 compared with PrAg. Thisdemonstrates that the introduction of the urokinase-activation
requirement, while not affecting the potency of this toxin, greatly
enhances its safety and, subsequently, its tumor selectivity.
Tumor-specific protease activation of bacterial toxins is an effective
strategy for the selectively targeting of a wide array of tumors and
other diseases, with some tumor protease-activated toxins, such as a
PSA-activated proaerolysin toxin, reaching advanced stages of clinical
development for prostate cancer and benign prostatic hyperplasia
[27–29]. We believe that this strategy becomes even more useful
when applied to toxins that possess another selectivity criterion,
generating dual-selective toxins such as PrAgU2/LF. In this study, we
provide a proof of principle for the efficacy of PrAgU2/LF in both
AML cell lines and primary AML blasts as well as for its increased
specificity and both in vitro and in vivo safety.
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Figure 6. Kaplan-Meier curves of female Balb/c mice treated with PrAg/LF or PrAgU2/LF every other day for a total of three doses (A).
Y-axis represents percent survival; X-axis represents days. PrAgU2/LF did not cause mortality at any dose. PrAg/LF had a mortality rate
ranging from 10% to 100% for doses ranging from 20 μg of PrAg/4 μg of LF (diamond) to 35 μg of PrAg/17 μg of LF (square). (B) Control
liver with normal parenchyma and a centrilobular vein (H&E ×200). (C) Liver parenchyma with numerous foci of perivenular and lobular
necroinflammation in a mouse treated with 25 μg of PrAg/5 μg of LF (H&E ×200). (D) Liver parenchyma with numerous foci of perivenular
and lobular necroinflammation in a mouse treated with 30 μg of PrAg/6 μg of LF (H&E ×200). (E) Liver parenchyma with rare microscopic
foci of lobular necroinflammation in a mouse treated with 75 μg of PrAgU2/15 μg of LF (H&E ×400).
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